Yipurun (Shanghai) Biotechnology’s Corina Intrauterine Drug-Eluting System, a drug-device-combination therapy, has received approval in China for treating moderate-to-severe intrauterine adhesions (IUA).
The system is designed for treating patients with IUA who undergo transcervical resection of adhesions (TCRA) and offers a new therapeutic option in the field of female reproductive health.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This approval follows a randomised controlled clinical trial that demonstrated Corina’s efficacy in comparison to the standard-of-care.
IUA, which result from damage to the uterus’s endometrial basal layer, can lead to severe reproductive health issues, including infertility and recurrent miscarriage.
With an incidence rate of up to 25% in Chinese women who have undergone certain uterine procedures, the condition represents a significant health concern.
Despite the high incidence of intrauterine adhesions and the common use of transcervical resection of adhesions as a treatment, the recurrence rate remains alarmingly high, the company said.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe approval for Corina introduces an approach to reducing this rate and improving pregnancy outcomes post-surgery.
Corina combines a non-degradable medical-grade material with estradiol, leveraging Yipurun’s proprietary technology to release the drug over a 60-day period.
This promotes endometrial growth and acts as a physical barrier to prevent re-adhesion.
The clinical trial results for Corina have shown a statistically significant reduction in intrauterine adhesion and an improvement in endometrial thickness at 60 days post-procedure, marking a significant advance in the treatment of this condition.
Yipurun is a wholly-owned subsidiary of Puyi (Shanghai) Biotechnology (Puyi Biotech).
Puyi Biotech and YPR have developed an R&D pipeline of high-end implantable therapeutics leveraging knowhow in biomedical material science and proprietary drug-eluting technology.
